Juvenile spondyloarthropathies and related arthritis

Current Opinion in Rheumatology

Volumn 14, Issue 5, 2002, Pages 531-535

  Bukulmez, Hulya ^a   Colbert, Robert A ^a  

^a Cincinnati Childrens Hosp Med Ctr   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BISPHOSPHONIC ACID DERIVATIVE; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTHRALGIA; ARTHRITIS; CARDIOMYOPATHY; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MYALGIA; OSTEOPOROSIS; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; UVEITIS; VALVULAR HEART DISEASE; ADOLESCENT; DRUG ANTAGONISM; PATHOLOGY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CHILD; DIPHOSPHONATES; HUMAN; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036707731     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200209000-00009     Document Type: Review

References (38)

1. Criteres de classification des spondyloarthropathies
2. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy
3. New York symposium on population studies in the rheumatic diseases: New diagnostic criteria
4. A syndrome of seronegative enthesopathy and arthropathy in children
5. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997
6. Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria
7. The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice
8. Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloarthropathies
9. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides
10. HLA-B27 and pathogenesis of spondyloarthropathies
11. Inflammatory eye, skin, and bowel disease in spondyloarthritis: Genetic, phenotypic, and environmental factors
12. Prevalence of uveitis in an outpatient juvenile arthritis clinic: Onset of uveitis more than a decade after onset of arthritis
13. The ocular manifestations of juvenile rheumatoid arthrits
14. Uveitis in sibling pairs with juvenile idiopathic arthritis
15. Undifferentiated spondyloarthropathies: A 2-year follow-up study
16. Two-dimensional echo Doppler findings in juvenile and adult onset ankylosing spondylitis with long-term disease
17. Radiologic changes of ischial tuberosity in ankylosing spondylitis
18. Etanercept in children with polyarticular juvenile arthritis
19. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period
20. Use of Infliximab in pediatric patients with inflammatory bowel disease
21. Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade with infliximab on the articular symptoms
22. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study
23. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
24. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα
25. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondyloarthropathy
26. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumor necrosis factor α
27. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: One year follow up
28. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis
29. Treatment of ankylosing spondylitis with infliximab
30. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-α monoclonal antibody infliximab
31. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (Infliximab) versus placebo in active spondyloarthropathy
32. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
33. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy
34. Nitrogen-containing bisphophonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
35. Bisphosphonates in vitro specifically inhibit, among the hematopoeitic series, the development of the mouse mononuclear phagocyte lineage
36. Clinical and radiologic amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate
37. An open study of pamidronate in the treatment of refractory ankylosing spondylitis
38. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis